Charles Breen, MD
Family Medicine · Hillsboro, NDNPI 1114944113
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 124 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 18.9% — the pattern of someone who eats at a lot of different presentations.
Across 124 payments — averaging $11.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$266
- Boehringer Ingelheim$241
- Johnson & Johnson$129
- AbbVie$82
- Phathom Pharmaceuticals, Inc.$67
- Lilly USA, LLC$62
- plus $566 from 24 others
What the payments were for
- Food & beverage$1,412100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 30 | $266 |
| Boehringer Ingelheim | 17 | $241 |
| Johnson & Johnson | 22 | $129 |
| AbbVie(2 entities) | 5 | $82 |
| Phathom Pharmaceuticals, Inc. | 7 | $67 |
| Lilly USA, LLC | 4 | $62 |
| Mylan Specialty L.p. | 4 | $57 |
| Acadia Pharmaceuticals Inc | 3 | $49 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $44 |
| Novartis | 3 | $40 |
| Sanofi-aventis U.S. LLC | 2 | $38 |
| E.r. Squibb & Sons, L.L.C. | 2 | $35 |
| Astellas Pharma US Inc | 2 | $33 |
| Merck | 2 | $32 |
| AstraZeneca | 2 | $26 |
| Lundbeck LLC | 1 | $20 |
| Abbott | 1 | $18 |
| Sanofi | 1 | $18 |
| Pfizer | 1 | $17 |
| Nestle Healthcare Nutrition Inc. | 1 | $17 |
| Viatris Specialty LLC | 1 | $14 |
| Alkermes, Inc. | 1 | $14 |
| Exact Sciences | 1 | $14 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
| Sanofi Pasteur Inc. | 1 | $13 |
| Esperion Therapeutics, Inc. | 1 | $12 |
| Bayer | 1 | $12 |
| Biogen | 1 | $11 |
| Eisai Inc. | 1 | $11 |
| Dynavax Technologies Corporation | 2 | $7 |
How this compares
$1,412 in reported general payments places this provider in the 85th percentile of 337 family medicine providers in North Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 294 | $158,486 |
| JardianceEmpagliflozin | 132 | $93,031 |
| XareltoRivaroxaban | 111 | $47,560 |
| OzempicSemaglutide | 45 | $46,820 |
| FarxigaDapagliflozin Propanediol | 33 | $25,386 |
| MyrbetriqMirabegron | 90 | $24,496 |
| JanuviaSitagliptin Phosphate | 19 | $20,600 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 48 | $18,450 |
| AbrysvoRsv Vacc, Pref A And Pref B/Pf | 49 | $16,586 |
| YupelriRevefenacin | 11 | $16,553 |
| EntrestoSacubitril/Valsartan | 11 | $14,424 |
| MultaqDronedarone Hcl | 12 | $12,102 |
| Atorvastatin Calcium | 805 | $9,573 |
| Metoprolol Succinate | 466 | $9,499 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 39 | $9,349 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Abrysvo | $17 | $175,072343 claims |
| Boehringer IngelheimJardiance | $241 | $93,031132 claims |
| Johnson & JohnsonXarelto | $129 | $47,560111 claims |
| Novo NordiskOzempic | $266 | $46,82045 claims |
| AstraZenecaFarxiga, Symbicort | $26 | $28,90047 claims |
| Astellas Pharma US IncMyrbetriq | $33 | $24,49690 claims |
| MerckJanuvia | $32 | $20,60019 claims |
| Mylan Specialty L.p.Yupelri | $57 | $16,55311 claims |
| NovartisEntresto | $40 | $14,42411 claims |
| Sanofi-aventis U.S. LLCMultaq | $38 | $12,10212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 337 family medicine providers in North Dakota.
Other family medicine in Hillsboro
- Timothy LuithleHillsboro$2K
- Richard VetterWest Fargo$294K
- Thomas ThorsonMandan$241K
- Gregory GreekGrand Forks$216K
- Katherine NeubauerWest Fargo$160K
- Spencer BerryFargo$81K
- Eric JohnsonGrand Forks$52K
- Stuart TopleyFargo$24K
- Jacqueline QuisnoBismarck$19K
- Jeffrey SmithBismarck$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.